SRTD Names Matthias Alder Chief Executive

Company SRTD Biotech Event Type CEO appointment Modality Selectively expressed mRNA; fusogenic LNP Asset seRNA platform (preclinical) Target Disease-associated intracellular RNA markers Disease Area Oncology; autoimmune disease; fibrosis Summary Recovered source-gap leadership item: SRTD Biotech identified Matthias Alder as its newly appointed CEO in its…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *